Fairmount Funds Management LLC
CIK 1802528
13F filing for Q2 2026・No. 1,987
- Holdings
- US$1.51B
- Quarter change
- +US$128.63M
- Entries
- 12
- Net bought (estimate)
- −US$163.01M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 1
- Sold out 1
- Cut 0
- Added 1
- Corporate actions 0
- Unchanged 10
Largest holdings
12 stocks worth US$1.51B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| ORUKA THERAPEUTICS INCCOM | Unchanged | 3,705,262 | US$352.63M | 23.31% |
| DIANTHUS THERAPEUTICS INCCOM | Unchanged | 2,537,191 | US$247.33M | 16.35% |
| DAMORA THERAPEUTICS INCCOM NEW | Unchanged | 8,713,000 | US$226.63M | 14.98% |
| COGTCOGENT BIOSCIENCES INCCOM | Unchanged | 5,503,418 | US$212.98M | 14.08% |
| JADE BIOSCIENCES INCCOM NEW | Unchanged | 4,553,494 | US$101.18M | 6.69% |
| ELVNENLIVEN THERAPEUTICS INCCOM | Unchanged | 1,855,644 | US$94.17M | 6.22% |
| VIRIDIAN THERAPEUTICS INCCOM | Added | 5,090,928 | US$93.52M | 6.18% |
| ZENAS BIOPHARMA INCCOM | Unchanged | 2,359,025 | US$59.87M | 3.96% |
| CRESCENT BIOPHARMA INC.COM | Unchanged | 2,747,866 | US$49.46M | 3.27% |
| APGEAPOGEE THERAPEUTICS INCCOM | Unchanged | 298,647 | US$39.64M | 2.62% |
Sign in (free) to see its 12 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.